The inhibitory role of methylation on the binding characteristics of dopamine receptors and transporter

Neuroscience Research

Volumn 48, Issue 3, 2004, Pages 335-344

  Lee, Eun Sook Y ^a   Chen, Hongtao ^a   Shepherd, Kennie R ^a   Lamango, Nazarius S ^a   Soliman, Karam F A ^a   Charlton, Clivel G ^b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Dopamine binding; Dopamine D1 receptor; Dopamine D2 receptor; Methanol; Methylation; Parkinson's disease; S Adenosylmethionine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBOXYL GROUP; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ESTER; LIGAND; METHANOL; METHYL GROUP; S ADENOSYLMETHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; HYDROLYSIS; INJECTION; MALE; METHYLATION; MOLECULAR CLONING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RAT; SYNTHESIS; TISSUE DISTRIBUTION;

EID: 1242271259     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2003.11.010     Document Type: Article

References (49)

1. Alderson T. Formaldehyde-induced mutagenesis: a novel mechanism for its action. Mutat. Res. 154:1985;101-110.
2. 2 classification. Trends Pharmacol. Sci. 11:1990;231-236.
3. Aoyama K., Matsubara K., Okada K., Fukushima S., Shimizu K., Yamaguchi S., Uezono T., Satomi M., Hayase N., Ohta S., Shiono H., Kobayashi S. N-Methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J. Neural Transm. 107:2000;985-995.
4. Aoyama K., Matsubara K., Kondo M., Murakawa Y., Suno M., Yamashita K., Yamaguchi S., Kobayashi S. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci. Lett. 298:2001;78-80.
5. Audubert F., Vance D.E. Pitfalls and problems in studies on the methylation of phosphatidylethanolamine. J. Biol. Chem. 258:1983;10695-10701.
6. Axelrod J. Brain monoamines. Biosynthesis and fate. Neurosci. Res. Program Bull. 9:1971;188-196.
7. Backlund P.S. Jr., Simonds W.F., Spiegel A.M. Carboxyl methylation and COOH-terminal processing of the brain G-protein gamma-subunit. J. Biol. Chem. 265:1990;15572-15576.
8. 1 receptor antagonist ligand, in rat striatum Life Sci. 35:1984;1885-1893.
9. Black, R.A., Hobson, A.C., Adler, J., 1982. In: Usdin, E., Borchardt, R.T., Creveling, C.R. (Eds.), Biochemistry of S-adenosylmethionine and Related Compounds, Macmillan, London, pp. 91-98.
10. 3H ] spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy Eur. J. Pharmacol. 99:1984;167-175.
11. Bontemps F., Van Den Berghe G. Metabolism of exogenous S-adenosylmethionine in isolated rat hepatocyte suspensions: methylation of plasma-membrane phospholipids without intracellular uptake. Biochem J. 327:1997;383-389.
12. Bonuccelli U., Colzi A., Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin. Neuropharmacol. 25:2002;1-10.
13. 1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J. Neurochem. 49:1987;1075-1083.
14. Charlton C.G., Mack J. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. Mol. Neurobiol. 9:1994;149-161.
15. Charlton C.G., Way E.L. Tremor induced by S-adenosyl-L-methionine: possible relation to L-dopa effects. J. Pharm. Pharmacol. 30:1978;819-820.
16. Collins M.A., Neafsey E.J., Matsubara K., Cobuzzi R.J. Jr., Rollema H. Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res. 570:1992;154-160.
17. Crews F.T., Calderini G., Battistella A., Toffano G. Age dependent changes in the methylation of rat brain phospholipids. Brain Res. 229:1981;256-259.
18. Crowell B.G. Jr., Benson R., Shockley D., Charlton C.G. S-adenosyl-L-methionine Decreases Motor Activity in the Rat: similarity to Parkinson's disease-like Symptoms. Behav. Neural Biol. 59:1993;186-193.
19. Diliberto E.J. Jr., Axelrod J. Characterization and substrate specificity of a protein carboxymethylase in the pituitary gland. Proc. Natl. Acad. Sci. U.S.A. 71:1974;1701-1704.
20. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
21. Gagnon C., Kelly S., Manganiello V., Vaughan M., Odya C., Strittmatter W., Hoffman A., Hirata F. Modification of calmodulin function by enzymatic carboxylic methylation. Nature. 291:1981;515-516.
22. Gearhart D.A., Collins M.A., Lee J.M., Neafsey E.J. Increased β-carboline 9 N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol. Dis. 7:2000;201-211.
23. Green S., Buttrum S., Molloy H., Steventon G., Sturman S., Waring R., Pall H., Williams A. N-Methylation of pyridines in Parkinson's disease. Lancet. 338:1991;120-121.
24. 2 receptor density remains constant in treated Parkinson's disease. Ann. Neurol. 19:1986;487-492.
25. Hirata F., Axelrod J. Enzymatic methylation of phosphatidylethanolamine increases erythrocyte membrane fluidity. Nature. 275:1978;219-220.
26. Hornykiewicz, O., 1982. Brain neurotransmitters changes in Parkinson's disease. In: Marsden, C.D., Fahn, S. (Eds.), Movement Disorders, Butterworth Scientific, London, pp. 41-58.
27. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964.
28. Johnson B.A., Langmack E.L., Aswad D.W. Partial repair of deamidation-damaged calmodulin by protein carboxyl methyltransferase. J. Biol. Chem. 262:1987;12283-12287.
29. Kopin I.J. Monoamine oxidase and catecholamines metabolism. J. Neural Transm. Suppl. 41:1994;57-67.
30. Ladino C.A., O'Connor C.M. Methylation of atypical protein aspartyl residues during the stress response of HeLa cells. J. Cell. Physiol. 153:1992;297-304.
31. Laduron P.M., Ilien B. Solubilization of brain muscarinic, dopaminergic and serotonergic receptors: a critical analysis. Biochem. Pharmacol. 31:1982;2145-2151.
32. Lamango S.N., Charlton C.G. Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol. Biochem. Behav. 66:2000;841-849.
33. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
34. +) increases S-adenosyl-L-methionine dependent phospholipid methylation. Pharmacol. Biochem. Behav. 70:2001;105-114.
35. Leprohon C.E., Blusztajn J.K., Wurtman R.J. Dopamine stimulation of phosphatidylcholine (lecithin) biosynthesis in rat brain neurons. Proc. Natl. Acad. Sci. U.S.A. 80:1983;2063-2066.
36. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6,-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
37. 3H ]-YM-09151-2 Naunyn-Schmiedebergs Arch. Pharmacol. 329:1985;333-343.
38. Oliveira C.R., Duarte E.P., Carvalho A.P. Effect of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding. J. Neurochem. 43:1984;455-465.
39. Park, I.K., Paik, W.K., 1990. The occurrance and analysis of methylated amino acids. In: Paik, W.K., Kim, S. (Eds.), Protein Methylation, CRC Press, Boca Raton, FL, pp. 1-22.
40. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease Eur. J. Pharmacol. 114:1985;235-237.
41. 1 receptors in the putamen of control and Parkinsonian subjects Eur. J. Pharmacol. 113:1985;467-468.
42. Rinne J.O., Laihinen A., Lonnberg P., Marjamaki P., Rinne U.K. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res. 556:1991;117-122.
43. 1 receptors in the Parkinsonian brain. Brain Res. 359:1985;306-310.
44. Scatchard G. The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 51:1949;660-672.
45. Scholz J., Bamberg H., Moser A. N-Methyl-norsalsolinol, an endogenous neurotoxin, inhibits tyrosine hydroxylase activity in the rat brain nucleus accumbens in vitro. Neurochem. Int. 31:1997;845-849.
46. Sharma A., Kramer M.L., Wick P.F., Liu D., Chari S., Shim S., Tan W., Ouellette D., Nagata M., DuRand C.J., Kotb M., Deth R.C. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol. Psychiatry. 4:1999;235-246.
47. Vincent P.L., Siegel F.L. Carboxylmethylation of calmodulin in cultured pituitary cells. J. Neurochem. 49:1987;1613-1622.
48. Williams A.C., Pall H.S., Steventon G.B., Green S., Buttrum S., Molloy H., Waring R. N-Methylation of pyridines and Parkinson's disease. Adv. Neurol. 60:1993;194-196.
49. Wolf M.E., Roth R.H. Dopamine autoreceptor stimulation increases protein carboxyl methylation in striatal slices. J. Neurochem. 44:1985;291-298.